Binds Plasma Protein, Serum Protein, Or Fibrin (e.g., Clotting Factor, Fibrinolytic Factor, Complement Factor, Immunoglobulin, Apolipoprotein, Etc.) Patents (Class 530/389.3)
-
Patent number: 11634504Abstract: The invention relates to antibodies, and antigen-binding fragments thereof, that specifically bind TFPI and inhibit an activity thereof. Such antibodies and fragments are useful for treating bleeding disorders and shortening clotting time.Type: GrantFiled: November 24, 2020Date of Patent: April 25, 2023Assignee: Pfizer Inc.Inventors: Debra Pittman, James R. Apgar, Zong Sean Juo, Macy Jin, Mark Stahl, Gregory J. Carven, Matthew Holsti, Susan Benard, Sunita R. Hett, Reema Jasuja
-
Patent number: 11498960Abstract: The disclosure provides engineered polypeptides that specifically bind to human complement component C5 and/or serum albumin. The disclosure also provides fusion proteins comprising such engineered polypeptides, wherein such fusion proteins may be multivalent and multi-specific fusion proteins. The disclosure further provides nucleic acid molecules that encode such engineered polypeptides or fusion proteins, and methods of making such engineered polypeptides or fusion proteins. The disclosure further provides pharmaceutical compositions that comprise such engineered polypeptides or fusion proteins, and methods of treatment using such engineered polypeptides or fusion proteins.Type: GrantFiled: July 11, 2018Date of Patent: November 15, 2022Assignee: Alexion Pharmaceuticals, Inc.Inventors: Bridget Puffer, Julian Chandler, Nimish Gera, Douglas L. Sheridan, Siddharth Jindal, Paul P. Tamburini
-
Patent number: 9017957Abstract: An object of the present invention is to provide an antibody that can be stably supplied and can react with prostasin under non-denaturation and denaturation conditions, and an antigen peptide for preparation of the antibody. The present invention relates to a peptide consisting of the amino acid sequence shown in SEQ ID NO: 1 or a peptide consisting of an amino acid sequence that has a deletion, a substitution, or an addition of one or several amino acids with respect to the amino acid sequence shown in SEQ ID NO: 1 and having antigenicity of prostasin. Furthermore, the present invention relates to an antibody prepared using the peptide as an antigen.Type: GrantFiled: May 1, 2007Date of Patent: April 28, 2015Assignees: Hitachi Chemical Company, Ltd., Kimio Tomita, Kenichiro KitamuraInventors: Hiromi Iijima, Noriya Ohta, Kimio Tomita, Kenichiro Kitamura
-
Patent number: 9012154Abstract: The present invention relates to methods for detecting Ficolin-3 dependent activation of the lectin pathway of complement, methods for identifying abnormalities in Ficolin-3, and methods for screening for deficiencies/and or identifying abnormalities in any downstream components of the Ficolin-3 dependent activation of the lectin pathway of 5 complement using an acetylated Ficolin-3 ligand, said methods generally comprising the steps of: (a) providing a sample of blood, serum, plasma, another body fluid or an extract thereof; (b) (optionally) preventing in the sample activation of the classical pathway and/or the alternative pathway and/or any non-Ficolin-3 mediated activation of the lectin pathway; (c) acetylating a molecule; (d) contacting said acetylated molecule 10 with said sample, in conditions that permit specific binding of Ficolin-3 to said acetylated molecule, and, (e) detecting and quantifying specific binding of the Ficolin-3 to said acetylated molecule, (f) determining in the sample complement acType: GrantFiled: June 9, 2010Date of Patent: April 21, 2015Assignees: Rigshospitalet, University of CopenhagenInventors: Peter Garred, Christian Honore
-
Patent number: 9000134Abstract: The invention provides reagents and methods for diagnosing kidney disease in a human or animal.Type: GrantFiled: May 12, 2008Date of Patent: April 7, 2015Inventors: Wallace B. Haigh, Donald L. Very, Jr.
-
Publication number: 20150087813Abstract: The invention provides a dual-specific ligand comprising a first immunoglobulin variable domain having a first binding specificity and a complementary or non-complementary immunoglobulin variable domain having a second binding specificity.Type: ApplicationFiled: February 5, 2014Publication date: March 26, 2015Applicant: Domantis LimitedInventors: Kevin MOULDER, Ian Tomlinson
-
Patent number: 8945860Abstract: The present invention relates to compositions and highly sensitive methods for the detection of biotechnology product residual when monitoring product carry over and/or for cleaning verification in the manufacture of biotechnology products. In particular, the present invention is directed to immunoassays wherein one or more capture antibodies, or antigen binding fragments thereof, are used to detect residuals associated with the production of biotechnology products.Type: GrantFiled: September 13, 2011Date of Patent: February 3, 2015Assignee: Abbvie Inc.Inventors: Lihua Yang, Natarajan Ramasubramanyan
-
Patent number: 8927220Abstract: A protein used as a biomarker for diagnosing IgA nephropathy and TGBM (thin-glomerular-basement-membrane) using urine through a target proteomics method. A diagnosis biomarker protein and a kit for diagnosing IgA nephropathy and TGBM and predicting progress of the nephropathy in advance using the protein are provided. The degree of the progression of the disease can be grasped by detecting IgA nephropathy and TGBM, enabling early diagnosis and confirming progress from the patient's urine. In addition, a monoclonal antibody produced based on the diagnosis biomarker protein can be used for an immunoassay kit (ELISA, antibody coated tube test, lateral-flow test, potable biosensor). The monoclonal antibody is used in early diagnosis and progression detection of IgA nephropathy and development of a novel drug for the purpose of treatment.Type: GrantFiled: September 30, 2009Date of Patent: January 6, 2015Assignee: Kyungpook National University Industry-Academic Cooperation FoundationInventors: Moon Chang Baek, Pyong Gon Moon, Yong Lim Kim
-
Patent number: 8921528Abstract: Drug compositions, fusions and conjugates are provided. The drug fusions and conjugates contain a therapeutic or diagnostic agent that is fused or conjugated to an antigen-binding fragment of an antibody that binds serum albumin. The drug compositions, fusions and conjugates have a longer in vivo half-life in comparison with the unconjugated or unfused therapeutic or diagnostic agent.Type: GrantFiled: May 31, 2005Date of Patent: December 30, 2014Assignee: Domantis LimitedInventors: Lucy J. Holt, Ian M. Tomlinson
-
Publication number: 20140378653Abstract: This application relates to neurological inflammatory diseases, such as multiple sclerosis, and to methods of administering a Factor XII inhibitor to prevent, treat, or otherwise ameliorate the effects of a neurological inflammatory disease, such as multiple sclerosis. Agents and pharmaceutical compositions comprising agents which inhibit the activity of FXII are also provided.Type: ApplicationFiled: January 31, 2013Publication date: December 25, 2014Inventors: Sven Meuth, Kerstin Goebel, Christoph Kleinschnitz, Brent McKenzie, Marc Nolte
-
Patent number: 8906633Abstract: The invention describes methods and kits for detecting and determining current and future synthetic cannabinoids from the JWH and CP families. Unique antibodies derived from novel immunogens enable said methods and kits.Type: GrantFiled: December 20, 2011Date of Patent: December 9, 2014Assignee: Randox Laboratories LimitedInventors: Elouard Benchikh, Stephen Peter Fitzgerald, Paul John Innocenzi, Philip Andrew Lowry, Ivan Robert McConnell
-
Publication number: 20140348762Abstract: Described herein are methods for identifying a mammal having a heightened susceptibility to enamel erosion, together with kits therefor and uses and methods related thereto.Type: ApplicationFiled: December 20, 2011Publication date: November 27, 2014Applicant: COLGATE-PALMOLIVE COMPANYInventors: Lynette Zaidel, Steven Miller, Guy Carpenter, Gordon Proctor, David Bartlett, Rebecca Moazzez
-
Publication number: 20140302033Abstract: A serum albumin binding antibody or fragment thereof comprising a heavy chain variable domain having the sequence given in SEQ ID NO: 1 or SEQ ID NO:2 and/or comprising a light chain variable domain having the sequence given in SEQ ID NO:3 or SEQ ID NO:4, in particular comprising a heavy chain variable domain and a light chain variable domain having the sequence given in SEQ ID NO: 1 and SEQ ID NO:3 or a heavy chain variable domain and a light chain variable domain having the sequence given in SEQ ID NO: 2 and SEQ ID NO:4. The disclosure also extends to polynucleotides encoding the antibodies or fragments, vectors comprising same and host cells capable of expressing the polynucleotides. The disclosure further includes pharmaceutical compositions comprising the antibodies or fragments and therapeutic used of any one of the same.Type: ApplicationFiled: November 9, 2012Publication date: October 9, 2014Applicant: UCB PHARMA S.A.Inventors: Ralph Adams, Pavalli Bhatta, Sam Phillip Heywood, David Paul Humphreys
-
Publication number: 20140286964Abstract: The present invention provides methods for designing agents such as ligands capable of binding to a Janus kinase (Jak), particularly a Jak2 JH2, and especially a JH2 V617F, screening methods for identifying agents such as ligands and small molecules capable of binding to the same, and computer assisted methods for designing and identifying such agents. Further, the present invention provides methods for treating myeloproliferative neoplasias (MPNs) along with agents such as ligands and small molecules identified or designed using the methods described.Type: ApplicationFiled: October 24, 2012Publication date: September 25, 2014Inventors: Stevan R. Hubbard, Rajintha M. Bandarayanake, Olli Silvennoinen, Daniela Ungureanu
-
Publication number: 20140248282Abstract: As a result of producing anti-DDR1 antibodies and conducting extensive studies on the antitumor activity thereof, antibodies that bind to the stalk domain in the amino acid sequence of human DDR1 were found to have a potent activity even when used alone compared to antibodies that bind to other domains. It was also found that the antibodies have one or more activities selected from the group consisting of: (i) an activity to suppress cell proliferation, (ii) an activity to inhibit cell migration, (iii) an activity to inhibit phosphorylation of DDR1 in cells, (iv) an activity to be taken up into cells, (v) an activity to decrease the expression level of DDR1 in cells, and (vi) an activity to decrease the expression level of TGF-? in cells.Type: ApplicationFiled: August 23, 2012Publication date: September 4, 2014Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHAInventors: Mei Ono, Yuji Sano, Tsukasa Suzuki
-
Patent number: 8822653Abstract: Plasma kallikrein binding proteins and methods of using such proteins are described.Type: GrantFiled: January 6, 2011Date of Patent: September 2, 2014Assignee: Dyax Corp.Inventors: Daniel J. Sexton, Malini Viswanathan
-
Patent number: 8816055Abstract: Plasma kallikrein binding proteins and methods of using such proteins are described.Type: GrantFiled: January 6, 2012Date of Patent: August 26, 2014Assignee: Dyax Corp.Inventors: Daniel J. Sexton, Malini Viswanathan
-
Publication number: 20140234988Abstract: Non-mercaptalbumin-2 is used as a biomarker for diagnosing a medical condition associated with oxidative stress. A method for diagnosing a condition associated with oxidative stress includes determining the redox state of albumin at the cysteine residue at sequence position 34; quantifying the level of non-mercaptalbumin-2 present, non-mercaptalbumin-2 representing the albumin fraction irreversibly oxidized at cysteine 34; and comparing the result to a control level, wherein an elevated level of non-mercaptalbumin-2 as compared to the control level is indicative of the condition associated with oxidative stress.Type: ApplicationFiled: August 14, 2012Publication date: August 21, 2014Applicant: MEDIZINISCHE UNIVERSITAET GRAZInventors: Carolin Lackner, Karl Oettl, Rudolf Stauber, Ruth Birner-Gruenberger
-
Publication number: 20140228546Abstract: The present invention relates to amino acid sequences that are capable of binding to serum albumin; to proteins and polypeptides comprising or essentially consisting of such amino acid sequences; to nucleic acids that encode such amino acid sequences, proteins or polypeptides; to compositions, and in particular pharmaceutical compositions, that comprise such amino acid sequences, proteins and polypeptides; and to uses of such amino acid sequences, proteins and polypeptides.Type: ApplicationFiled: June 14, 2012Publication date: August 14, 2014Applicant: Ablynx N.V.Inventors: Bruno Dombrecht, Peter Schotte, Cedric Josef Neotere Ververken
-
Patent number: 8802096Abstract: The present invention relates to binding moieties that specifically bind to a conformational epitope of C5a, in particular human C5a. Preferred binding moieties are anti-C5a antibodies that bind to this conformational epitope. The binding moieties described herein are useful as active agents in pharmaceutical compositions for the treatment and prevention of various acute and chronic diseases, in particular acute inflammatory diseases, such as the systemic inflammatory response syndrome (SIRS), and different degrees of sepsis including sepsis, severe sepsis, and septic shock.Type: GrantFiled: November 26, 2010Date of Patent: August 12, 2014Assignee: Inflarx GmbHInventors: Renfeng Guo, Niels Christoph Riedemann, Yan Li, Beifen Shen
-
Publication number: 20140212433Abstract: The invention relates to anti-Factor D antibodies, their nucleic acid and amino acid sequences, the cells and vectors that harbor these antibodies and their production and their use in the preparation of compositions and medicaments for treatment of diseases and disorders associated with excessive or uncontrolled complement activation. These antibodies are useful for diagnostics, prophylaxis and treatment of disease.Type: ApplicationFiled: March 5, 2014Publication date: July 31, 2014Applicant: Genentech, Inc.Inventors: ARTHUR HUANG, ROBERT KELLEY, HENRY LOWMAN, MENNO VAN LOOKEREN CAMPAGNE, CHARLES WINTER
-
Publication number: 20140194600Abstract: The present invention relates to binding molecules such as antibodies that specifically bind plasma coagulation factor XI and that inhibit factor XI activation and/or activity. The factor XI-binding molecules of the invention may used in methods for preventing or treating diseases, disorders and/or conditions that are mediated by factor XI activation and/or wherein inhibition of factor XI has a beneficial effect.Type: ApplicationFiled: September 24, 2013Publication date: July 10, 2014Applicant: Prothix B.V.Inventor: Erik HACK
-
Publication number: 20140186365Abstract: Antibodies that specifically bind to an epitope on the serum albumin, including human and/or mouse serum albumin are provided. Nucleic acids encoding such antibodies and cells capable of expressing such antibodies are also provided.Type: ApplicationFiled: March 14, 2013Publication date: July 3, 2014Applicants: Institute for Cancer Research d/b/a The Research Institute of Fox Chase Cancer Center, Oncobiologics, Inc.Inventors: Matthew K. Robinson, John K. Cini, Jimson W. D'Souza
-
Patent number: 8759489Abstract: The present invention relates to an antibody that recognizes a first antibody, the antibody specifically recognizing one of a free first antibody and an antigen-binding first antibody. More specifically, the above antibody is a domino antibody that specifically recognizes and binds to an antigen-binding first antibody, or an antibody-unlocking antibody that specifically recognizes and binds to a free first antibody.Type: GrantFiled: August 24, 2011Date of Patent: June 24, 2014Assignees: Otsuka Pharmaceutical Co., Ltd., Tokyo University of ScienceInventors: Takachika Azuma, Hisao Takizawa
-
Publication number: 20140140996Abstract: The invention relates to improved anti-serum albumin immunoglobulin single variable domains, as well as ligands and drug conjugates comprising such variable domains, compositions, nucleic acids, vectors and hosts.Type: ApplicationFiled: January 30, 2014Publication date: May 22, 2014Applicant: Glaxo Group LimitedInventors: Edward COULSTOCK, Elena De Angelis, Haiqun Liu, Oliver Schon
-
Publication number: 20140087965Abstract: The present invention relates to a marker which can be used to diagnose a diabetic retinopathy patient and determine the progression of diabetic retinopathy, a composition for diagnosing diabetic retinopathy, which comprises an agent for measuring the level of a gene or protein associated with the marker, and the use thereof.Type: ApplicationFiled: September 25, 2013Publication date: March 27, 2014Applicants: SNU R&DB FOUNDATION, LG ELECTRONICS INC.Inventors: Yunhee KU, Youngsoo KIM, Seungyeon SONG, Jonghwa JIN, Moosub KIM, Yongju YANG
-
Publication number: 20140081003Abstract: The present invention relates to methods and compositions for preventing incorporation of norleucine into proteins during recombinant protein production in bacteria. The present invention also provides microorganism host cells and nucleic acid molecules for use with the methods and compositions provided herein.Type: ApplicationFiled: September 19, 2013Publication date: March 20, 2014Applicant: Genentech, Inc.Inventors: Michael W. Laird, Karthik Veeravalli
-
Patent number: 8663598Abstract: One embodiment of the disclosure provides an amino sequence of an anti-human transferrin receptor antibody, including: an amino sequence of a heavy chain variable region which is represented by SEQ ID NO.: 1 or SEQ ID NO.: 2, wherein the anti-human transferrin receptor antibody is capable of specifically binding to a human transferrin receptor.Type: GrantFiled: September 11, 2012Date of Patent: March 4, 2014Assignee: Industrial Technology Research InstituteInventors: Ming-Hua Yang, Min-Yuan Chou, Hsiang-Ching Wang
-
Publication number: 20130331282Abstract: Disclosed herein is a marker composition that includes sphingosine 1-phosphate (S1P) protein and that may be used to predict the risk of fracture or osteoporosis; a kit that includes an antibody that specifically binds to the S1P protein and that can be used to predict the risk of fracture or osteoporosis; and a method that can be used to obtain information that allows prediction of the risk of fracture or osteoporosis and includes measurements of S1P protein concentrations by measuring the binding of a S1P-specific antibody to S1P protein. The S1P protein disclosed herein is highly expressed in individuals with fracture, regardless of their bone mineral density. Accordingly, it may be useful as a biomarker of the risk of fracture or osteoporosis.Type: ApplicationFiled: April 18, 2013Publication date: December 12, 2013Inventors: Jung Min Koh, Ghi Su Kim, Seung Hun Lee, Beom Jun Kim
-
Publication number: 20130323751Abstract: This invention is related to the field of the prevention and treatment of kidney disease. The treatment of kidney disease may be tailored depending upon the need for, or expectation of, renal recovery. For example, renal recovery can be determined by monitoring urine biomarkers related to the development of chronic kidney disease. For example, a normalized time course of approximately fourteen Days measuring urinary proteins can be used to establish the risk of recovery versus non-recovery in patient's having suffered an acute kidney injury. Alternatively, the invention describes signature protein expression profiles to establish the probability of renal to recovery and/or renal non-recovery.Type: ApplicationFiled: January 20, 2012Publication date: December 5, 2013Applicant: University of Pittsburgh - of the Common-Wealth System of Higher EducationInventors: Kai Singbartl, John A. Kellum, JR.
-
Publication number: 20130302333Abstract: The invention concerns the prevention and treatment of complement-associated eye conditions, such as choroidal neovascularization (CNV) and age-related macular degeneration (AMD), by administration of Factor D antagonists.Type: ApplicationFiled: June 27, 2013Publication date: November 14, 2013Applicant: GENENTECH, INC.Inventors: Philip Hass, Yin Jianping, Kenneth Katschke, JR., Micah Steffek, Christian Weismann, Menno Van Lookeren Campagne
-
Publication number: 20130266973Abstract: The invention provides anti-idiotypic HCMV antibodies as well as methods of using the same.Type: ApplicationFiled: March 15, 2013Publication date: October 10, 2013Inventors: Jo-Anne Hongo, Yanhong Li, Luna Liu, John Lowe, Mauricio Maia, Rajesh Vij, Terence Wong, Keyang XU
-
Publication number: 20130259801Abstract: A method for purifying serum amyloid P protein from fresh unfrozen plasma, includes recalcifying the fresh unfrozen plasma and separation by phenyl-type hydrophobic interaction chromatography. The serum amyloid P protein is also obtainable by the method and the use thereof for therapeutic treatment purposes. A method for determining amyloid deposits in a tissue or organ of a subject is also provided.Type: ApplicationFiled: December 16, 2011Publication date: October 3, 2013Applicant: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIESInventors: Catherine Chenou, Jean-François Prost
-
Patent number: 8501427Abstract: The invention relates to antibodies, including monoclonal and polyclonal, or fragments thereof, which discriminate between the histidine and tyrosine isoforms of Complement Factor H and to their use in diagnostic methods and therapeutic treatments relating to Complement Factor H mediated diseases.Type: GrantFiled: January 23, 2008Date of Patent: August 6, 2013Assignee: University College Cardiff Consultants LimitedInventors: Bryan Paul Morgan, Claire Louise Harris, Svellana Hakobyan
-
Patent number: 8497350Abstract: The invention relates to Factor H gene polymorphisms and haplotypes associated with an elevated or a reduced risk of AMD. The invention provides methods and reagents for diagnosis and treatment of AMD.Type: GrantFiled: June 5, 2009Date of Patent: July 30, 2013Assignee: University of Iowa Research FoundationInventor: Gregory S. Hageman
-
Patent number: 8486657Abstract: It is disclosed herein that antibodies specific for preproproteins or preproteins, which are synthesized by certain types of cells or tissues, can be used in immunohistochemistry assays to discriminate between the intracellular component of the protein (including the preproprotein, preprotein and/or proprotein forms of the protein) from the secreted component of the same protein. Accordingly, provided herein is an immunohistochemical method for specific detection of the intracellular form of a protein in a biological sample using an antibody specific for the preproprotein or preprotein form of the protein. In particular examples, the protein is albumin or an immunoglobulin light chain. Also disclosed herein are preproprotein-specific ore preprotein-specific antibodies that can be used to detect specific cell types, tissue lesions or other pathological foci and metastases by IHC. In particular, antibodies that specifically bind human preproalbumin, but do not bind the secreted form of albumin are disclosed.Type: GrantFiled: March 22, 2010Date of Patent: July 16, 2013Inventors: Xiaohong Cai, Thomas Cai
-
Publication number: 20130172535Abstract: The invention includes a process for extracting a target protein from E. coli cells that includes lowering the pH of a whole E. coli cell solution to form an acidic solution, disrupting the cells to release the protein into the acidic solution, and separating the cellular debris from the released protein to obtain a protein product enriched in the heterologous target protein. The invention also includes addition of a solubility enhancer.Type: ApplicationFiled: June 29, 2012Publication date: July 4, 2013Inventor: Richard L. Gehant
-
Publication number: 20130157291Abstract: Disclosed is a diagnostic marker for lung cancer comprising Hp?R as an active ingredient. Because blood, which is relatively easy to sample, is employed as a specimen, the diagnostic kit and marker for lung cancer is very simple and does not subject patients to a load compared to conventional methods that are directed to a biopsy. In addition, the kit and marker of the present invention is useful in the early diagnosis of lung cancer thanks to its high diagnostic sensitivity and selectivity.Type: ApplicationFiled: June 29, 2011Publication date: June 20, 2013Inventor: Il Han Kim
-
Publication number: 20130136736Abstract: The present invention relates to improved Nanobodies™ against von Willebrand Factor (vWF), as well as to polypeptides comprising or essentially consisting of one or more of such Nanobodies. The invention also relates to nucleic acids encoding such Nanobodies and polypeptides; to methods for preparing such Nanobodies and polypeptides; to host cells expressing or capable of expressing such Nanobodies or polypeptides; to compositions comprising such Nanobodies, polypeptides, nucleic acids or host cells; and to uses of such Nanobodies, such polypeptides, such nucleic acids, such host cells or such compositions, in particular for prophylactic, therapeutic or diagnostic purposes, such as the prophylactic, therapeutic or diagnostic purposes.Type: ApplicationFiled: January 4, 2013Publication date: May 30, 2013Applicant: Ablynx N.V.Inventor: Karen Silence
-
Publication number: 20130129746Abstract: The invention relates to improved variants of the anti-serum albumin immunoglobulin single variable domain DOM7h-11, as well as ligands and drug conjugates comprising such variants, compositions, nucleic acids, vectors and hosts.Type: ApplicationFiled: May 20, 2011Publication date: May 23, 2013Inventors: Elena De Angelis, Carolyn Enever, Haiqun Liu, Oliver Schon, Malgorzata Pupecka-Swider
-
Publication number: 20130115621Abstract: Disclosed are antibodies that selectively bind to blood coagulation factor FVIII, and highly sensitive immunological assays comprising these antibodies. Preferred assays can detect FVIII at about 3500-fold below the normal physiological levels, and have a wide array of applications including accurate monitoring of FVIII concentration in pharmaceutical products for treatment of blood coagulation disorders, and determination of FVIII levels in plasma of human patients, including those with blood coagulation disorders such as hemophilia.Type: ApplicationFiled: July 18, 2012Publication date: May 9, 2013Applicant: The University of Vermont and State Agriculture CollegeInventors: Behnaz Parhami-Seren, Kenneth G. Mann, David N. Fass
-
Patent number: 8415113Abstract: A procedure for the identification of a functional disorder of the pancreas by the use of parts of all iso-enzymes of the pancreas elastase and of synthetic amino-acid sequences as antigens for obtaining specific antibodies, as well as their use in immuno-chemical test procedures.Type: GrantFiled: September 3, 1999Date of Patent: April 9, 2013Assignee: R-Biopharm AGInventors: Hans-Werner Heinrich, Rainer Kleinert, Udo Meyer, Heinz-Jürgen Wagner
-
Publication number: 20130078245Abstract: The present invention relates to methods and materials for modulating the complement alternative pathway (CAP), the complement classical pathway (CCP), the complement lectin/mannose pathway (CMP), or combinations thereof, as well as methods and materials for targeting prophylactic or therapeutic agents to localized areas of tissue within the body where they may more directly exert their effects upon the intended target cells or tissue, with reduced, associated systemic effects compared with administration of the same or similar agents in an untargeted, systemic manner. The methods and materials of the present invention may therefore allow for increased efficacy, lower threshold effective dosages and/or lower effective maintenance doses, and/or reduced associated undesired or adverse effects in terms of frequency or severity of occurrence, or both.Type: ApplicationFiled: August 17, 2012Publication date: March 28, 2013Applicant: The Regents of the University of Colorado, a body CorporateInventors: V. Michael Holers, Joshua M. Thurman, Liudmila Kulik
-
Publication number: 20130052202Abstract: The invention relates to high affinity human monoclonal antibodies, particularly those directed against isotypic determinants of immunoglobulin E (IgE), as well as direct equivalents and derivatives of these antibodies. These antibodies bind to their respective target with an affinity at least 100 fold greater than the original parent antibody. These antibodies are useful for diagnostics, prophylaxis and treatment of disease.Type: ApplicationFiled: July 27, 2012Publication date: February 28, 2013Inventors: Sanjaya Singh, Herren Wu, Catherine Foster
-
Publication number: 20130052128Abstract: The present disclosure relates to binding agents (e.g. antibodies) that bind to and/or modulate the activity of a urokinase plasminogen activator receptor (uPAR/CD87), compositions comprising the antibodies, and methods involving use of the antibodies or compositions.Type: ApplicationFiled: February 11, 2011Publication date: February 28, 2013Inventors: Charles S. Craik, Krishna Sai Duriseti, David H. Goetz
-
Publication number: 20130045180Abstract: Improved vaccines which include a nucleotide sequence that encodes immunomodulating protein operably linked to regulatory elements are disclosed. The improved vaccines include DNA vaccines, recombinant vaccines for delivering foreign antigen and live attenuated vaccines. Methods of immunizing individuals are disclosed. Compositions for and methods of treating individuals with autoimmune diseases are disclosed.Type: ApplicationFiled: January 27, 2012Publication date: February 21, 2013Inventors: David B. Weiner, Jong J. Kim, Jeong-Im Sin
-
Publication number: 20130039925Abstract: A method of selecting a genus of therapeutic antibodies includes selecting antibodies with the following criteria; a) do inhibit cell lysis under conditions wherein the alternative pathway is isolated from the classical pathway; and b) do not inhibit cell lysis under conditions wherein the classical pathway is isolated from the alternative pathway; and c) do not inhibit cell lysis under conditions wherein the classical pathway and alternative pathway are active; and d) do inhibit C3b produced exclusively by the alternative pathway;Type: ApplicationFiled: October 5, 2012Publication date: February 14, 2013Inventor: Rekha Bansal
-
Publication number: 20130011869Abstract: Provided are an antibody capable of specifically and accurately measuring digested products of stabilized fibrin (D-dimer), and a method and a reagent for measuring D-dimer using the antibody. The antibody specifically reacts with D-dimer, which is plasmin-digested products of stabilized fibrin, but does not react with fibrinogen or plasmin-digested products of fibrinogen, which include fragment X, fragment Y, fragment D1, and fragment E3, and does not react with dissociation products of DD/E monomer, which include fragment DD, fragment E1, and fragment E2.Type: ApplicationFiled: March 31, 2011Publication date: January 10, 2013Applicant: Mitsubishi Chemical Medience CorporationInventors: Yutaka Nagahama, Junko Nozaki, George Sakurai
-
Publication number: 20130004485Abstract: An isolated anti-properdin antibody or antigen binding portion thereof includes a heavy chain variable domain including the 3CDRs in SEQ ID NO: 1 and light chain variable domain including the 3 CDRS in SEQ ID NO: 9.Type: ApplicationFiled: March 10, 2011Publication date: January 3, 2013Inventor: Rekha Bansal
-
Publication number: 20120328628Abstract: The present invention provides methods for generating antibodies to specific conformations of proteins. The conformation specific antibodies of the invention can be put to a variety of uses including diagnosis and treatment of diseases and for screening for compounds that induce conformational changes in proteins upon binding.Type: ApplicationFiled: July 6, 2007Publication date: December 27, 2012Applicant: The Regents of the University of CaliforniaInventors: James A. Wells, Junjun Gao